The federal judge overseeing the Provigil antitrust litigation has awarded attorneys representing end-payers nearly $22 million in fees.

U.S. District Judge Mitchell Goldberg of the Eastern District of Pennsylvania on Tuesday awarded $21.9 million to leading attorneys representing the group of consumers and companies that paid for the drug after Cephalon, the company that makes the sleep disorder drug, allegedly entered into agreements with generic drug makers to delay the entry of competitors on the market. Goldberg’s ruling in the case, captioned Vista Health Plan v. Cephalon, also gave final approval to the nearly $66 million settlement the parties entered into to settle the end-payers’ claims.